

Title (en)
REMEDIES FOR DISEASES CAUSED BY VASCULAR CONTRACTION OR DILATION

Title (de)
ARZNEIMITTEL FÜR DURCH VASKULÄRE KONTRAKTION ODER DILATATION HERVORGERUFENE ERKRANKUNGEN

Title (fr)
REMÈDES POUR LES MALADIES PROVOQUÉES PAR LA CONTRACTION OU LA DILATATION VASCULAIRE

Publication
EP 1522314 B1 20140305 (EN)

Application
EP 03761797 A 20030625

Priority
• JP 0308039 W 20030625
• JP 2002185546 A 20020626

Abstract (en)
[origin: EP1522314A1] A therapeutic and/or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and/or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovascular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and/or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like. <IMAGE>

IPC 8 full level
A61K 45/00 (2006.01); **A61K 31/437** (2006.01); **A61K 31/445** (2006.01); **A61P 9/00** (2006.01); **A61P 9/06** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 9/14** (2006.01); **A61P 13/12** (2006.01); **A61P 25/06** (2006.01); **A61P 43/00** (2006.01); **C07D 211/48** (2006.01); **C07D 471/04** (2006.01); **C07D 519/00** (2006.01)

CPC (source: EP US)
A61K 31/437 (2013.01 - EP US); **A61K 31/445** (2013.01 - EP US); **A61P 3/06** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/04** (2017.12 - EP); **A61P 9/06** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 9/14** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 211/48** (2013.01 - EP US); **C07D 471/04** (2013.01 - EP US)

Citation (examination)
• DE 2801187 A1 19780720 - METABIO JOULLIE MEUDON FA
• WO 9907672 A1 19990218 - NOVO NORDISK AS [DK]
• US 5985873 A 19991116 - BLUM CHARLES A [US], et al
• WO 0205819 A1 20020124 - SMITHKLINE BEECHAM CORP [US], et al
• JP H08253484 A 19961001 - TAISHO PHARMA CO LTD
• WO 03051274 A2 20030626 - ASTRAZENECA AB [SE], et al
• WO 03049741 A1 20030619 - HOFFMANN LA ROCHE [CH]

Cited by
CN104248694A; EP2308562A3; AU2007321719B2; JP2014065713A; CN105189454A; AU2013273769B2; RU2639875C2; WO2008154470A1; WO2008058341A1; WO2009074969A3; US10231966B2; US11364238B2; US7776861B2; US8637548B2; US9301953B2; EP1698375B1; WO2005063704A1; US9925184B2; US7511159B2; US8461161B2; US9029386B2; US9815815B2; US10246438B2; US10532994B2; JP2010509375A; JP2015164925A

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
EP 1522314 A1 20050413; **EP 1522314 A4 20090916**; **EP 1522314 B1 20140305**; AU 2003248245 A1 20040119; DK 1522314 T3 20140526; EP 2508204 A2 20121010; EP 2508204 A3 20121212; EP 2508204 B1 20140924; ES 2464157 T3 20140530; JP 2012031201 A 20120216; JP 5387997 B2 20140115; JP WO2004002531 A1 20051027; PT 1522314 E 20140605; TW 200410688 A 20040701; US 2006148844 A1 20060706; US 8765783 B2 20140701; WO 2004002531 A1 20040108

DOCDB simple family (application)
EP 03761797 A 20030625; AU 2003248245 A 20030625; DK 03761797 T 20030625; EP 12005031 A 20030625; ES 03761797 T 20030625; JP 0308039 W 20030625; JP 2004517272 A 20030625; JP 2011239881 A 20111101; PT 03761797 T 20030625; TW 92117219 A 20030625; US 51911303 A 20030625